A decision support tool for development of drugs targeting central nervous system conditions. The tool receives measurements made on subjects, which are converted to model outputs using neurocircuitry models. The models are used by a computing device to generate neuro-circuitry based signatures. Neuro-circuitry based signatures associated with an investigational compound may be compared to reference neuro-circuitry based signatures to identify parameters of a clinical trial protocol. The neuro-circuitry based signature comparisons, when generated based on measurement data collected in early phases of a clinical trial process, may increase the likelihood that the investigational compound will quickly and cost-effectively emerge from clinical trials with proof that the investigational compound is effective for treating one or more CNS conditions. The decision support tool may also indicate early phase measurements to make based on a condition against which an investigational compound is theorized to be effective against.
